Amarin Corp Plcuk (AMRN) Other Non-Current Assets (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Other Non-Current Assets of $1.0 million for Q1 2026, down 13.97% year-over-year from $1.2 million in Q1 2025, and down 5.34% quarter-over-quarter from $1.1 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Other Non-Current Assets (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 17 years of Other Non-Current Assets data on file, last reported at $1.0 million in Q1 2026.

  • Other Non-Current Assets for Q1 2026 came in at $1.0 million, down 13.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 13.97% YoY), and the FY2025 annual result was $1.1 million, down 12.04% from the prior year.
  • Other Non-Current Assets retreated to $1.0 million in Q1 2026 per AMRN's latest filing, from $1.1 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $1.6 million in Q1 2023 and troughed at $456000.0 in Q1 2022.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2025 frame the typical range for Other Non-Current Assets.
  • The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets jumped 259.21% in 2023, then retreated 19.76% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $458000.0 in 2022, then jumped by 196.94% to $1.4 million in 2023, then slipped by 10.81% to $1.2 million in 2024, then slipped by 12.04% to $1.1 million in 2025, then slipped by 5.34% to $1.0 million in 2026.
  • Business Quant data shows AMRN's Other Non-Current Assets at $1.0 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.18 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.23 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 14.11 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 10.54 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 19.81 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 4.55 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 9.83 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 6.08 Bn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn 1.01 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.01 Mn
Dec 31, 2025 1.07 Mn
Sep 30, 2025 1.11 Mn
Jun 30, 2025 1.14 Mn
Mar 31, 2025 1.17 Mn
Dec 31, 2024 1.21 Mn
Sep 30, 2024 1.25 Mn
Jun 30, 2024 1.29 Mn
Mar 31, 2024 1.32 Mn
Dec 31, 2023 1.36 Mn
Sep 30, 2023 1.40 Mn
Jun 30, 2023 1.60 Mn
Mar 31, 2023 1.64 Mn
Dec 31, 2022 458,000.00
Sep 30, 2022 456,000.00
Jun 30, 2022 456,000.00
Mar 31, 2022 456,000.00
Dec 31, 2021 456,000.00
Sep 30, 2021 456,000.00
Jun 30, 2021 456,000.00